New treatment for advanced gastric cancer after prior therapies
Treatments studied
Part of Cancer, Digestive system clinical trials.
This study tests a new drug for people with advanced stomach cancer that has not responded to at least two prior treatments. The goal is to see if it is safe and tolerable, and whether it can slow the cancer's growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced stomach or GEJ cancer that has come back or spread.
- You have already tried two previous treatments and they are no longer working.
- You are able to be up and about (ECOG 0 or 1 — meaning fully active or able to do light work).
- You have at least one tumor that can be measured on a scan.
- You have not had major surgery in the last 4 weeks or planned during the trial.
- You do not have untreated or quickly growing brain metastases.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of new drugs (SHR-1701, Rivoceranib, and possibly SHR-2554) for people with advanced stomach cancer whose disease has continued to grow after immunotherapy. It aims to find a better treatment option for those who have not had success with standard therapy.
This trial tests a combination of three drugs (adebrelimab, apatinib, and liposomal irinotecan) for people with advanced gastric or gastroesophageal junction cancer whose first treatment stopped working. The goal is to see if this new combination can help when standard options have failed.
This study tests a new combination of drugs (apatinib, nab-paclitaxel, and possibly adebrelimab) for advanced stomach or gastroesophageal junction cancer that has progressed after initial treatment. The goal is to see if this combination can help control the cancer.
This Phase I/II trial tests how well irinotecan combined with tislelizumab (an immunotherapy) treats advanced stomach or gastroesophageal junction adenocarcinoma. It mainly looks at safety and the best way to use this combination, and may help shrink tumors or slow disease growth.
This trial tests a new drug combination (IBI363 plus Avastin) with or without chemotherapy (Abraxane) for people with advanced stomach or GE junction cancer that has already been treated with immunotherapy and other first-line therapy. The goal is to see if this new approach can help when the cancer has grown or stopped responding to prior treatment.
This study tests a new combination of targeted therapy (DP303c) with either a drug called simmitinib or a liposomal form of irinotecan for people with advanced stomach or GEJ cancer. The goal is to see if these combinations can shrink tumors or slow cancer growth.
Hear when a new Gastric Cancer (GC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.